MIRM Analysts Raise Targets After Earnings Beat

Mirum Pharmaceuticals reported earnings on November 3 and walked away with a fresh wave of analyst upgrades the following morning, making the Street's response to the print the most interesting thing on the tape this week.

Four firms raised their price targets on November 4 alone. Citizens lifted its target the furthest, from $144 to $167, while Cantor Fitzgerald moved from $155 to $160 and HC Wainwright edged to $202. RBC Capital held its $155 target and Outperform rating. The direction of travel is unmistakably bullish. The consensus mean target now sits at $153, against a close of $87, implying roughly 76% implied upside across the coverage universe. Every analyst with a fresh note maintained a Buy or Outperform equivalent. No one downgraded.

The bull case centres on a rare-disease franchise that is generating cash, with Livmarli approved in ALGS and PFIC, Cholbam and Ctexli adding commercial breadth, and the September approval of Atebrioz in fibrodysplasia ossificans progressiva adding a genuinely novel asset. The combined peak sales potential is pitched above $4bn under conservative assumptions, and the company carried $438m in net cash and short-term investments into the print. Bears counter that the valuation is entirely dependent on successful execution across multiple pipeline programs, and that any clinical setback, reimbursement pressure, or dilutive equity raise could remove a significant portion of the thesis. The PE is deeply negative and the EV/EBITDA multiple continues to widen, reflecting a company that is growing revenue but has not yet crossed into sustained profitability.

Short positioning tells a measured rather than alarming story, though it deserves attention at this level. Short interest has drifted down marginally this week, off about 0.8% from the prior week, to 13.1% of free float. That is a meaningful absolute level for a mid-cap biotech, but the lending market is not under any stress. Availability is wide at over 500% of short interest, meaning there are roughly five shares available to borrow for every one already borrowed. Borrowing costs are low at 0.5%. The ORTEX short score of 64 ranks in the lower fifth of the broader universe on a percentile basis, suggesting that while shorts have a real position, the setup is not an acute squeeze candidate right now. Options positioning is modestly constructive: the put/call ratio is at 0.53, slightly below its 20-day average of 0.55, and the z-score of minus 0.73 indicates there is marginally less defensive hedging than usual.

The activist register adds a noteworthy layer. Patrick J. Heron holds a Schedule 13D on Mirum, the most newsworthy classification in SEC ownership filings, as it signals potential activist intent. His stake was filed at 6.8% of the class as of January 2026, down from a prior filing at 7.6%. As always with 13D/G disclosures, positions are as last disclosed around the 5% threshold, and a holder who falls below 5% may not file again. Among institutional holders, FMR added nearly 1.7m shares in the most recent quarter, T. Rowe Price added 938k, and BlackRock added 543k. These are material additions from credible long-only names, and they were made before the earnings catalyst resolved. Janus Henderson remains the second-largest holder at 9.1% of shares.

One alt data point worth flagging: Medicaid reimbursement data from the Centers for Medicare and Medicaid Services showed units reimbursed up 268% year on year in Q1 2026, with Medicaid dollars reimbursed up 123% over the same period. No dataset in the ORTEX alt data coverage has been measured to lead Mirum's reported figures, so this cannot be called a leading indicator, but the magnitude of the Medicaid volume growth in the period covered is consistent with the commercial uptake story the bulls are building their case around.

The next earnings event is not until February 25, 2027, leaving 113 days for the market to either close the gap between the $87 share price and the $153 consensus target, or for the bears to find a catalyst that challenges the execution story. The key variable to watch is whether commercial momentum in Livmarli and Atebrioz holds into year-end, and whether short interest at 13% of float begins to drift lower as the post-earnings narrative firms up.